Who we are
About us
WE ARE CARDIO BIOLOGICS™
We are pioneering angiogenic gene therapies that harness the body’s natural healing mechanisms to restore blood flow in patients with advanced cardiovascular disease. Our lead candidate, CorGene (Ad5FGF-4), is designed to provide a new treatment option for patients with refractory angina who have limited alternatives today.
dNA + ANGIOGENESIS
Cardio Biologics™ is a newly-formed cardiovascular medical device and angiogenic gene therapy company that is focused on the development of a new and innovative angiogenic gene therapy product candidate delivered to the heart using minimally invasive radial artery access catheters and kit systems for the treatment of patients with refractory angina due to late-stage coronary artery disease who have exhausted pharmacological options and are not eligible for Percutaneous Coronary Intervention (PCI), or coronary artery bypass surgery.
Angiogenesis: Finding New Ways To Heal
